News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Promedior Attains Patient Enrollment Milestone In Phase 2 Clinical Study Of PRM-151 In Myelofibrosis


1/8/2014 9:04:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that it completed enrollment in the first stage of its adaptive Phase 2 trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. The Phase 2 trial rapidly completed enrollment, enrolling 25 patients in just over 12-weeks. Formally initiated in October 2013 at several sites in the United States and Canada, this first stage is expected to be completed in 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Promedior
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES